Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Assessing Relay Therapeutics (RLAY) Valuation After New ReDiscover Trial Data And FDA Breakthrough Status
Relay Therapeutics (RLAY) is under evaluation after releasing new Phase 1/2 ReDiscover trial data for zovegalisib, supporting its Phase 3 dosing regimen, and receiving FDA Breakthrough Status. Despite recent stock volatility, including a significant 1-year return, the company’s Price-to-Book ratio of 3x indicates investors are recognizing growth potential but also acknowledging risks like ongoing net losses. The article suggests investors should conduct their own due diligence to assess the company’s future prospects.